University of Antwerp
Welcome,         Profile    Billing    Logout  
 24 Trials 
13 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Vanderveken, Olivier M
EliSA, NCT04031040: A Post-market Clinical Follow up of the Genio™ System for the Treatment of Obstructive Sleep Apnea in Adults

Recruiting
N/A
110
Europe
Genio(TM) system therapy
Nyxoah S.A.
Obstructive Sleep Apnea
09/22
10/25
NCT02907398: Adherence and Outcome of Upper Airway Stimulation (UAS) for OSA International Registry

Active, not recruiting
N/A
5000
Europe, US
Inspire therapy, ADHERE, No intervention, CONTROL
Inspire Medical Systems, Inc.
Obstructive Sleep Apnea
09/25
12/25
verhoeven, veronique
VIAB2L, NCT06425081: Investigating the Impact of Humiome B2 (colon Delivered Riboflavin) and Riboflavin-overproducer Probiotic Strain Limosilactobacillus Reuteri AMBV339 on Intestinal and Vaginal Microbiome and Health of Healthy Adult Women (The Project)

Active, not recruiting
N/A
200
Europe
Limosilactobacillus reuteri AMBV339, Humiome B2, Limosilactobacillus reuteri AMBV339 + Humiome B2, Placebo
DSM Nutritional Products, Inc., Universiteit Antwerpen
Microbial Colonization
01/25
01/25
Smeets, Rob J
CIR-predict, NCT05661760: Predicting Successful Outcome of Interdisciplinary Biopsychosocial Rehabilitation in Osteoarthritis

Active, not recruiting
N/A
2309
Europe
interdisciplinary multimodal pain treatment, biopsychosocial treatment
Maastricht University, Centrum voor Integrale Revalidatie (CIR), Pfizer
Chronic Pain, Osteoarthritis, Disability Physical
01/22
12/23
Jansen, Anna
RAD-GRIN-201, NCT06392009: Astroscape: a Study of Radiprodil on Safety, Tolerability, Pharmacokinetics, and Effect on Seizures and Behavioral Symptoms in Patients with TSC or FCD Type II

Recruiting
1/2
30
Europe, Canada, RoW
Radiprodil
GRIN Therapeutics, Inc.
Tuberous Sclerosis Complex, Focal Cortical Dysplasia
07/25
07/26
Francque, Sven
NCT06165341: Study to Learn About the Safety of Fazirsiran and if it Can Help People With Alpha-1 Antitrypsin Liver Disease With Mild Liver Scarring (Fibrosis)

Recruiting
3
50
Europe, Canada, US
Fazirsiran Injection, TAK-999, ARO-AAT, ADS-001, Placebo
Takeda
Alpha1-Antitrypsin Deficiency
08/28
08/28
PRECIOSA, NCT03451292 / 2016-001789-28: Effects of Long-Term Administration of Human Albumin in Subjects With Decompensated Cirrhosis and Ascites

Completed
3
410
Europe, Canada, US, RoW
Albutein 20% Injectable Solution, Standard medical treatment
Grifols Therapeutics LLC, Instituto Grifols, S.A.
Decompensated Cirrhosis and Ascites
05/24
05/24
NATiV3, NCT04849728: A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( )

Recruiting
3
1000
Europe, Canada, US, RoW
IVA337, Lanifibranor, Placebo
Inventiva Pharma
NASH - Nonalcoholic Steatohepatitis
09/25
09/26
NCT05677971: Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein

Recruiting
3
160
Europe, Canada, US, RoW
Fazirsiran Injection, TAK-999, ARO-AAT, ADS-001, Placebo, Sodium chloride
Takeda, Takeda Development Center Americas, Inc.
Alpha1-Antitrypsin Deficiency
03/27
03/29
NAVIGATE, NCT04365868 / 2019-001983-31: Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH Cirrhosis

Active, not recruiting
2b
357
Europe, Canada, US, RoW
belapectin, GR-MD-02, galactoarabino rhamnogalacturonate, Placebo
Galectin Therapeutics Inc., Galectin Therapeutics Inc
Prevention of Esophageal Varices, NASH - Nonalcoholic Steatohepatitis, Cirrhosis
12/24
12/24
LEGEND, NCT05232071: Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With SGLT2 Inhibitor EmpaGliflozin in patiEnts With NASH and Type 2 Diabetes Mellitus

Completed
2
42
Europe, US
IVA337, Lanifibranor, Placebo, Empagliflozin, Jardiance
Inventiva Pharma
NASH - Nonalcoholic Steatohepatitis, Diabetes Mellitus, Type 2
03/24
06/24
VISTAS, NCT04663308 / 2020-003027-41: A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)

Recruiting
2
200
Europe, Canada, US, RoW
Volixibat, SHP626, Placebo
Mirum Pharmaceuticals, Inc., Mirum Pharmaceuticals, Inc.
Primary Sclerosing Cholangitis
09/25
12/25
HORIZON, NCT05583344 / 2022-002538-14: Phase 2b Study of GSK4532990 in Adults With NASH

Active, not recruiting
2
271
Europe, Canada, Japan, US, RoW
GSK4532990, Placebo
GlaxoSmithKline, GlaxoSmithKline Research & Development Limited
Nonalcoholic Fatty Liver Disease, Non-alcoholic Fatty Liver Disease
12/25
03/26
Coenen, Samuel
No trials found
Meeus, Mira
No trials found
Hallemans, Ann
No trials found
Bossaert, Leo
No trials found
Vervullens, Sophie
No trials found
Laer, Lien Van
No trials found
Meert, Lotte
No trials found
Baert, Isabel
No trials found
Massie, Zoë
No trials found

Download Options